Rabbit Anti-Human Thymocyte Immunoglobulin — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

8 Recruiting

3 Completed trials

12 Sponsors

12 Countries

Phase III

Phase II

Phase IV

Phase III: 2 Phase II/III: 1 Phase II: 6 Phase IV: 4

Indications tested

Myelodysplastic syndrome 2 Type 1 diabetes mellitus 1 Stem cell transplant 1 Relapsing-remitting multiple sclerosis 1

Sponsors using this IMP

Institut Paoli Calmettes 2 Assistance Publique Hopitaux De Paris 1 Centre Hospitalier Regional Universitaire De Tours 1 Centre hospitalier universitaire de Liege 1 Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S 1 Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca 1 Hospices Civils De Lyon 1 Hospital Universitario La Paz 1 Itb-Med AB 1 Ospedale San Raffaele S.r.l. 1 St. Anna Childrens Cancer Research Institute GmbH 1 Universitair Ziekenhuis Gent 1

All trials

13 total

A phase 2b, single-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of oral Ladarixin in associa… Not authorised

2025-524298-18-00 Phase II 1 country Ospedale San Raffaele S.r.l.
MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK BASED ON SELECTIVE BIOMARKERS (HLA EPLE… Pending

2025-520884-42-00 Phase IV 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia Recruiting

2024-512657-24-00 Phase II/III 12 countries St. Anna Childrens Cancer Research Institute GmbH
Use of tacrolimus and MTOR inhibitors with anticipatory therapy vs. tacrolimus and mycophenolic acid in renal recipients at high risk of pos… Recruiting

2025-520854-12-00 Phase IV 1 country Hospital Universitario La Paz
Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in Belgium Recruiting

2023-503723-26-00 Phase IV 1 country Universitair Ziekenhuis Gent
CASPER-ATG-IPC 2023-015 : Reinforced prophylaxis of GVH in elderly patients with haematological malignancies receiving haploidentical alloge… Recruiting

2023-506648-18-00 Phase II 1 country Institut Paoli-Calmettes
No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Recruiting

2024-515470-26-00 Phase II 1 country Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S
Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid l… Recruiting

2023-504555-27-00 Phase III 1 country Assistance Publique Hopitaux De Paris
INduction in Sensitized kidney Transplant recipients without pre-Existing donor-specific AntiboDies: a randomized multicentre trial between … Recruiting

2022-502007-30-00 Phase III 1 country Centre Hospitalier Regional Universitaire De Tours
Allogeneic hematopoietic cell transplantation from HLA-matched donor after Flu-Mel-PTCy versus Flu-Mel-ATG reduced-intensity conditioning: a… Recruiting

2024-518568-11-00 Phase II 1 country Centre Hospitalier Universitaire De Liege
Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin… Ended

2024-516435-27-00 Phase II 1 country Institut Paoli Calmettes
Pharmacokinetics of anti-lymphocyte serum in the prevention of GvHD in children and adults receiving allogeneic hematopoietic stem cell tran… Ended

2022-501594-39-00 Phase IV 1 country Hospices Civils De Lyon
A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti thymocyte … Ended

2023-507895-36-00 Phase II 3 countries Itb-Med AB

Showing 1–13 of 13 trials

← All drugs A–Z